The realm of extractables and leachables (E&L) continues to evolve, presenting both challenges and opportunities for professionals in the pharmaceutical and medical device sectors. A recent virtual conference aimed to shed light on these developments, gathering experts who shared insights on various critical topics related to E&L. This event marks the fourth installment in a series dedicated to understanding the complexities associated with E&L assessments.
E&L considerations are crucial during the development of medical products, as they can significantly impact product safety and efficacy. The conference featured a lineup of distinguished speakers who discussed relevant research findings and practical strategies for addressing E&L concerns. The topics covered ranged from regulatory compliance to analytical methodologies, providing attendees with a comprehensive understanding of the current landscape.
One of the key presentations came from Allan Ader, Co-founder of SafeBridge Consultants, who discussed the process of establishing Permitted Daily Exposure (PDE) values for E&L. Ader emphasized the importance of robust data in determining PDE values, illustrating the complexities that arise when data is limited. His insights highlighted the necessity for thorough risk assessments to ensure the safety of drug products.
Christopher T. Houston, a Senior Principal Scientist at Bausch & Lomb, addressed the unique challenges posed by E&L in ophthalmic drug products. He shared lessons learned from his extensive experience in analytical chemistry, showcasing successful strategies implemented within his organization to manage E&L testing effectively. Houston’s expertise underscored the importance of collaboration among multidisciplinary teams in tackling E&L issues.
The conference also featured Samuel Albeke, an LC Manager at VR Analytical, who presented on innovative sample enrichment approaches for E&L studies. His talk emphasized the need for advanced techniques to handle chromatographically challenging matrices, vital for generating accurate and reliable results in E&L assessments.
Shane Smith, Managing Director of ExtLe Solutions, shared a compelling case study on the risks associated with leachables when modifying small single-use system components in biopharmaceutical manufacturing. His findings served as a reminder of the potential implications that even minor changes in manufacturing processes can have on product safety.
James Pink, Senior Director at Element Materials Technology, discussed the regulatory aspects surrounding combination products and the implications of Article 117 of the European Union Medical Device Regulation (EUMDR). His insights provided a framework for understanding how regulatory changes impact E&L assessments and the importance of staying informed in an evolving regulatory landscape.
Gyorgy Vas, a Business Technical Scientific Liaison at Intertek Pharmaceutical Services, presented on the impact of injection solvents in gas chromatography-mass spectrometry (GC-MS) and their influence on the relative responses of common extractables. His research highlighted the intricacies involved in E&L testing and the necessity for precise analytical methods to ensure compliance with regulatory standards.
The conference served as a platform for networking and knowledge exchange among industry professionals. The discussions not only highlighted the importance of E&L in the pharmaceutical and medical device sectors but also showcased the dedication of experts to advancing the field through collaborative efforts and innovative research.
As the landscape of E&L continues to shift, professionals must remain vigilant and adaptive. Here are some key takeaways from the conference:
- Establishing PDE values requires comprehensive data analysis and a thorough understanding of toxicological implications.
-
Collaboration among various scientific disciplines is essential for effective E&L management, particularly in specialized fields like ophthalmology.
-
Innovative sample enrichment techniques can enhance the accuracy of E&L studies, especially in challenging analytical environments.
-
Regulatory changes, such as those outlined in the EUMDR, necessitate ongoing education and adaptation in E&L practices.
-
Understanding the nuances of analytical methods, including GC-MS, is crucial for accurate E&L assessments.
In summary, the conference reinforced the significance of E&L in ensuring the safety and efficacy of pharmaceutical and medical products. As the industry navigates an increasingly complex regulatory environment, ongoing education and collaboration will be vital for success.
Read more about it here → pharmtech.com
Read more on pharmtech.com